- Home
- ZENV vs NSPR Comparison
ZENV vs NSPR Comparison
Compare ZENV & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- NSPR
- Stock Information
- Founded
- ZENV 2005
- NSPR 2005
- Country
- ZENV Brazil
- NSPR United States
- Employees
- ZENV N/A
- NSPR N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- NSPR Medical/Dental Instruments
- Sector
- ZENV Technology
- NSPR Health Care
- Exchange
- ZENV Nasdaq
- NSPR Nasdaq
- Market Cap
- ZENV 79.2M
- NSPR 75.1M
- IPO Year
- ZENV 2021
- NSPR N/A
- Fundamental
- Price
- ZENV $1.49
- NSPR $2.24
- Analyst Decision
- ZENV
- NSPR Strong Buy
- Analyst Count
- ZENV 0
- NSPR 2
- Target Price
- ZENV N/A
- NSPR $4.50
- AVG Volume (30 Days)
- ZENV 74.1K
- NSPR 362.0K
- Earning Date
- ZENV 07-02-2025
- NSPR 08-05-2025
- Dividend Yield
- ZENV N/A
- NSPR N/A
- EPS Growth
- ZENV N/A
- NSPR N/A
- EPS
- ZENV N/A
- NSPR N/A
- Revenue
- ZENV $155,164,999.00
- NSPR $7,027,000.00
- Revenue This Year
- ZENV $8.58
- NSPR $4.85
- Revenue Next Year
- ZENV $8.83
- NSPR $113.47
- P/E Ratio
- ZENV N/A
- NSPR N/A
- Revenue Growth
- ZENV 18.83
- NSPR 8.49
- 52 Week Low
- ZENV $1.02
- NSPR $1.99
- 52 Week High
- ZENV $3.03
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- ZENV 49.27
- NSPR 41.35
- Support Level
- ZENV $1.45
- NSPR $1.99
- Resistance Level
- ZENV $1.59
- NSPR $2.33
- Average True Range (ATR)
- ZENV 0.16
- NSPR 0.15
- MACD
- ZENV -0.01
- NSPR -0.02
- Stochastic Oscillator
- ZENV 29.07
- NSPR 47.50
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.